Prestige BioPharma Statistics

Total Valuation

KRX:950210 has a market cap or net worth of KRW 159.50 billion. The enterprise value is 193.01 billion.

Market Cap	159.50B
Enterprise Value	193.01B

Important Dates

The last earnings date was Friday, May 30, 2025.

Earnings Date	May 30, 2025
Ex-Dividend Date	n/a

Share Statistics

KRX:950210 has 12.02 million shares outstanding. The number of shares has increased by 0.07% in one year.

Current Share Class	n/a
Shares Outstanding	12.02M
Shares Change (YoY)	+0.07%
Shares Change (QoQ)	-0.31%
Owned by Insiders (%)	30.40%
Owned by Institutions (%)	0.09%
Float	3.59M

Valuation Ratios

The trailing PE ratio is 36.68.

PE Ratio	36.68
Forward PE	n/a
PS Ratio	18.41
PB Ratio	0.29
P/TBV Ratio	0.40
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	8.86
EV / Sales	22.28
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.95

Financial Position

The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.27.

Current Ratio	1.38
Quick Ratio	1.23
Debt / Equity	0.27
Debt / EBITDA	n/a
Debt / FCF	-1.50
Interest Coverage	-8.41

Financial Efficiency

Return on equity (ROE) is 0.04% and return on invested capital (ROIC) is -5.90%.

Return on Equity (ROE)	0.04%
Return on Assets (ROA)	-5.17%
Return on Invested Capital (ROIC)	-5.90%
Return on Capital Employed (ROCE)	-10.08%
Revenue Per Employee	160.42M
Profits Per Employee	403.48M
Employee Count	54
Asset Turnover	0.01
Inventory Turnover	0.08

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +52.53% in the last 52 weeks. The beta is 1.08, so KRX:950210's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	+52.53%
50-Day Moving Average	13,816.00
200-Day Moving Average	14,604.95
Relative Strength Index (RSI)	45.44
Average Volume (20 Days)	136,850

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:950210 had revenue of KRW 8.66 billion and earned 21.79 billion in profits. Earnings per share was 361.82.

Revenue	8.66B
Gross Profit	7.44B
Operating Income	-62.24B
Pretax Income	348.07M
Net Income	21.79B
EBITDA	-42.51B
EBIT	-62.24B
Earnings Per Share (EPS)	361.82

Full Income Statement

Balance Sheet

The company has 213.27 billion in cash and 148.52 billion in debt, giving a net cash position of 64.75 billion or 5,387.47 per share.

Cash & Cash Equivalents	213.27B
Total Debt	148.52B
Net Cash	64.75B
Net Cash Per Share	5,387.47
Equity (Book Value)	541.08B
Book Value Per Share	7,357.04
Working Capital	66.32B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -61.21 billion and capital expenditures -37.75 billion, giving a free cash flow of -98.97 billion.

Operating Cash Flow	-61.21B
Capital Expenditures	-37.75B
Free Cash Flow	-98.97B
FCF Per Share	-8,234.01

Full Cash Flow Statement

Margins

Gross margin is 85.94%, with operating and profit margins of -718.46% and 251.52%.

Gross Margin	85.94%
Operating Margin	-718.46%
Pretax Margin	4.02%
Profit Margin	251.52%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

KRX:950210 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.07%
Shareholder Yield	-0.07%
Earnings Yield	13.66%
FCF Yield	-62.05%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KRX:950210 has an Altman Z-Score of -0.27. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.27
Piotroski F-Score	n/a